Endogenous opioids upregulate brain-derived neurotrophic factor mRNA through delta- and micro-opioid receptors independent of antidepressant-like effects

The European Journal of Neuroscience
Huina ZhangM C Ko

Abstract

Systemic administration of delta-opioid receptor (DOR) agonists decreases immobility in the forced swim test (FST) and increases brain-derived neurotrophic factor (BDNF) mRNA expression in rats, indicating that DOR agonists may have antidepressant-like effects. The aim of this study was to investigate the effects of central administration of endogenous opioid peptides on behavior in the FST and on brain BDNF mRNA expression in rats. Effects of endogenous opioids were compared with those produced by intracerebroventricular administration of a selective non-peptidic DOR agonist (+)BW373U86. Antidepressant-like effects were measured by decreased immobility in the FST. BDNF mRNA expression was determined by in situ hybridization. Centrally administered (+)BW373U86 decreased immobility and increased BDNF mRNA expression in the frontal cortex through a DOR-mediated mechanism, because these effects were blocked by the DOR antagonist naltrindole, but not by the micro-opioid receptor (MOR) antagonist naltrexone (NTX) or the kappa-opioid receptor antagonist nor-binaltorphimine. Of all the endogenous opioids tested, only leu- and met-enkephalin produced behavioral effects like those of (+)BW373U86 in the FST. Unlike (+)BW373U86, the enkep...Continue Reading

References

Oct 1, 1978·Pharmacology, Biochemistry, and Behavior·A J KastinD H Coy
Sep 1, 1977·Archives of General Psychiatry·N S KlineT Cooper
Jan 1, 1992·Research in Experimental Medicine. Zeitschrift Für Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie·S K BhattacharyaA P Sen
Sep 1, 1992·The American Journal of Psychiatry·D F DarkoS Golshan
Jul 1, 1991·Medicinal Research Reviews·E J Simon
Jul 1, 1988·Trends in Neurosciences·A MansourS J Watson
Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
Jan 1, 1983·Life Sciences·A G HayesM B Tyers
Sep 1, 1995·Pharmacology, Biochemistry, and Behavior·P Tejedor-RealJ Gibert-Rahola
Jun 1, 1994·Journal of Neurochemistry·R L ZastawnyB F O'Dowd
Jan 1, 1997·Pharmacology, Biochemistry, and Behavior·J A SiuciakR M Lindsay
Oct 12, 2000·Psychopharmacology·K A CarriganD T Lysle
Dec 21, 2000·Trends in Pharmacological Sciences·B P Roques
Aug 25, 2001·Annual Review of Neuroscience·E J Huang, L F Reichardt
May 15, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Daniel C BroomJames H Woods
May 15, 2002·Trends in Pharmacological Sciences·John F CryanIrwin Lucki
Aug 16, 2002·Bipolar Disorders·Carrol D'Sa, Ronald S Duman
Oct 3, 2002·Neuropeptides·C Gavériaux-Ruff, B L Kieffer
Mar 12, 2003·Trends in Pharmacological Sciences·Marzia Malcangio, Volkmar Lessmann
Apr 5, 2003·The Journal of Pharmacology and Experimental Therapeutics·M C H KoJ R Traynor
Dec 3, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mary M TorregrossaJames H Woods
Jan 15, 2004·The Journal of Pharmacology and Experimental Therapeutics·Emily M JutkiewiczJames H Woods
May 18, 2004·Brain Research. Brain Research Reviews·Kenji HashimotoMasaomi Iyo
Jun 17, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Amelia A Russo-NeustadtMichael J Chen
Nov 3, 2004·Growth Factors·Devin K Binder, Helen E Scharfman
Dec 2, 2004·Peptides·Richard J Bodnar, Gad E Klein

❮ Previous
Next ❯

Citations

Aug 6, 2013·International Journal of Molecular Sciences·Xuesong TianYing Xia
Dec 12, 2012·Trends in Neurosciences·Pierre-Eric Lutz, Brigitte L Kieffer
Apr 8, 2015·Physiology & Behavior·Khawla Q NuseirManal I Kassab
Sep 18, 2010·Hippocampus·Andrea Gómez-Palacio Schjetnan, Martha L Escobar
Aug 5, 2018·CNS Neuroscience & Therapeutics·Jin-Zhong HuangYing Xia
Mar 3, 2007·Pharmacological Reviews·Jakub FichnaJean-Claude Do Rego
Feb 24, 2015·Medicine and Science in Sports and Exercise·Jay R HoffmanHagit Cohen
Jan 9, 2020·Harvard Review of Psychiatry·Caroline A BrowneIrwin Lucki
Mar 25, 2020·Psychological Medicine·Caitlin A Madison, Shoshana Eitan
Apr 8, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Yue GengXuesong Tian
Oct 23, 2010·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Safa ElgamalGlenda MacQueen
Mar 24, 2016·The Pharmacogenomics Journal·R D HolmesJ L Kennedy
Sep 23, 2018·Children·Avneet K MangatGeorg M Schmölzer
Dec 11, 2019·Neuroscience and Biobehavioral Reviews·Corey B PuryearConnie Sanchez
Nov 7, 2020·Journal of Psychopharmacology·Luke A JelenJames M Stone
May 14, 2021·The Journal of Clinical Endocrinology and Metabolism·Logan K TownsendDavid C Wright
May 11, 2010·Biological Psychiatry·Suzanne Schol-GelokCornelia M van Duijn
Aug 12, 2010·Methods : a Companion to Methods in Enzymology·Bradley S CarterRobert C Thompson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.

© 2021 Meta ULC. All rights reserved